Analysts are weighing in on the Microbiome-focused company Synthetic Biologics Inc (NYSEMKT:SYN) and biopharmaceutical comapny Medivation Inc (NASDAQ:MDVN), with price targets ranging from 107% to 118% upside.
Synthetic Biologics Inc
In a research report issued yesterday, BTIG analyst Tim Chiang reiterated a Buy rating on shares of Synthetic Biologics, with a $5 price target, after the company announced the initiation of the second Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation.
Chiang noted, “The Co. indicated that more than half of the patients that had enrolled in the first Phase 2 study have enrolled into the second Phase 2 trial, which we believe is a positive sign. We believe key endpoints include a reduction in breath methane, as well as a potential increase in bowel movements and a lowering of abdominal pain levels.”
The analyst continued, “We recently met with the management team in NYC, and believe the Co. is making progress with both of its lead product candidates (SYN-010 and SYN-004 (a 2nd generation oral enzyme for the prevention of C. difficile infection and antibiotic-associated diarrhea. SYN recently initiated a Phase 2b proof of concept trial and has targeted the enrollment of ~370 patients.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Tim Chiang has a total average return of 15% and a 63.9% success rate. Chiang has a -5.2% average return when recommending SYN, and is ranked #450 out of 3772 analysts.
Out of the 5 analysts polled by TipRanks, 4 rate Synthetic Biologics stock a Buy, while 1 rates the stock a Hold. With a return potential of 173%, the stock’s consensus target price stands at $6.60.
In a research report released Friday, Canaccord analyst John Newman reiterated a Buy rating on shares of Medivation, with a price target of $90, following recent positive OS data for Xtandi in AR+ TNBC, which clinically validates antiandrogen approach in treating a defined subset of breast cancer, according to the analyst.
Newman noted, “Xtandi combinations may help overcome single agent resistance in other molecularly defined BC subtypes, HER2+ and ER+/PR+, representing a significantly larger market opportunity. We currently estimate US peak sales of $125-$300M for Xtandi in Androgen Receptor positive (AR+) Triple Negative Breast Cancer (TNBC) alone, but our calculations indicate a ~$900M opportunity in metastatic breast cancer outside of TNBC as well.”
“We speculate that Medivation will move forward with combination trials of their whollyowned assets in both prostate and breast cancers, utilizing talazoparib as a Xtandiamplifer. In a preclinical model, Schiewer et al demonstrated that PARP-1 inhibitors can enhance the effect of androgen depletion, suggesting that PARP-1 inhibitors could be used clinically to sensitize prostate cancer cells to AR-directed agents,” the analyst added.
According to TipRanks.com, analyst John Newman has a total average return of -3.1% and a 39.4% success rate. Newman has a -30.4% average return when recommending MDVN, and is ranked #3432 out of 3772 analysts.
Out of the 15 analysts polled by TipRanks, 9 rate Medivation stock a Buy, 5 rate the stock a Hold and 1 recommends a Sell. With a return potential of 56%, the stock’s consensus target price stands at $63.86.